What is the recommended treatment for severe asthma associated with fungal sensitization?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Severe Asthma with Fungal Sensitization

For acute severe asthma with fungal sensitization (SAFS) or allergic bronchopulmonary aspergillosis (ABPA), initiate either oral prednisolone 0.5 mg/kg/day for 2-4 weeks (tapered over 4 months) OR oral itraconazole 400 mg/day for 4 months as monotherapy. 1

Primary Treatment Options

The 2024 ISHAM guidelines provide Level I evidence that oral glucocorticoids are the most rapid-acting treatment for acute ABPA/SAFS, while oral itraconazole or voriconazole have similar efficacy with fewer adverse events (Level II evidence). 1

Prednisolone Regimen

  • Initial dose: 0.5 mg/kg/day for 2-4 weeks
  • Taper: Reduce gradually over 4 months total duration
  • Advantages: Fastest symptom control
  • Disadvantages: Higher adverse event profile (hyperglycemia, osteoporosis, weight gain, infections)

Itraconazole Regimen

  • Dose: 400 mg/day in two divided doses for 4 months (maximum 600 mg/day)
  • Administration: With meals to improve absorption (conventional capsule)
  • Advantages: Similar efficacy to steroids with better safety profile, steroid-sparing effect
  • Disadvantages: Slower trajectory to improvement

Critical drug interaction warning: Combining methylprednisolone with itraconazole significantly increases risk of exogenous Cushing's syndrome and adrenal insufficiency. Similarly, inhaled budesonide or fluticasone combined with itraconazole can cause Cushing's syndrome. 1

When to Use Combination Therapy

Reserve prednisolone plus itraconazole combination therapy ONLY for recurrent ABPA exacerbations, not for initial treatment. 1 Many clinicians use a practical approach: start with 2 weeks of glucocorticoids when initiating oral azole therapy, then transition to high-dose inhaled corticosteroids as symptoms improve. 1

Alternative Antifungal Options

If itraconazole fails or causes adverse events:

  • Voriconazole: 400 mg/day in two divided doses (maximum 600 mg/day), taken on empty stomach - showed 70-75% clinical response rates 2
  • Posaconazole: 800 mg/day (suspension) in two divided doses OR 300 mg/day (delayed-release tablet) once daily - achieves clinical remission in azole-intolerant patients (Level III evidence) 1

Biologic Therapy for Treatment-Dependent Disease

For patients requiring repeated courses of systemic therapy or unable to taper steroids:

Omalizumab has Level II evidence for reducing asthma exacerbations and steroid-sparing action in treatment-dependent ABPA/SAFS. 1 Real-world data shows sustained improvements in symptoms and exacerbations over 24 months in SAFS patients. 3

Other biologics (mepolizumab, benralizumab, dupilumab, tezepelumab) show promise with Level III evidence for steroid-sparing effects. 1

Monitoring and Follow-up

Do NOT routinely treat asymptomatic ABPA patients. However, individualize decisions for patients with:

  • Well-controlled asthma on high-dose inhaled steroids BUT CT shows bronchiectasis or mucus plugging
  • Prolonged mucus plugging (risk of irreversible bronchiectasis progression)

For untreated asymptomatic patients, monitor every 3-6 months with:

  • Clinical review
  • Chest radiograph
  • Serum total IgE levels

Key Clinical Pitfalls

  1. High-dose inhaled steroids alone do NOT achieve symptom control or reduce ABPA exacerbations when used as primary therapy (Level II evidence) 1

  2. SAFS represents a particularly severe phenotype - even with biologic therapy, these patients maintain higher disease severity scores, lower FEV1, higher exacerbation rates, and greater oral corticosteroid requirements compared to severe asthma without fungal sensitization 4

  3. Early-onset asthma is a risk factor for developing SAFS, with patients showing distinct airway inflammation profiles (higher FeNO, sputum eosinophilia/neutrophilia) 5

  4. Fungal sensitization prevalence is approximately twice as high in severe asthma (14.1%) versus non-severe asthma (7.1%) 5

The evidence strongly supports that SAFS/ABPA requires specific antifungal or anti-inflammatory management beyond standard severe asthma treatment to prevent irreversible bronchiectasis and achieve disease control. 1, 6

References

2
Research

Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.

The Journal of asthma : official journal of the Association for the Care of Asthma, 2012

3
Research

Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization.

The journal of allergy and clinical immunology. In practice, 2020

4
Research

Impact of Fungal Sensitization on Long-Term Outcomes in Severe Asthma.

The journal of allergy and clinical immunology. In practice, 2026

Related Questions

With Aspergillus-specific IgE of 0.48 kU/L and Aspergillus-specific IgG of 56.8 U, how can I determine if the patient has allergic bronchopulmonary aspergillosis and what additional tests are required?
What is the most likely diagnosis in a patient with asthma, recurrent wheezing, elevated total serum IgE >1000 IU/mL, Aspergillus-specific IgE positivity, eosinophilia, and central bronchiectasis with mucus plugging?
Is Xolair (Omalizumab) useful for Allergic Bronchopulmonary Aspergillosis (ABPA)?
In a patient with persistent asthma and a total serum IgE level of 224 IU/mL, could this represent allergic bronchopulmonary aspergillosis (ABPA)?
When should treatment be started for suspected allergic bronchopulmonary aspergillosis in a patient with asthma or cystic fibrosis who shows clinical deterioration and has supporting radiographic and immunologic findings?
Can hypercalcemia cause acute kidney injury?
How should dual antiplatelet therapy be managed in a patient with a recent myocardial infarction and subdural hematoma who has never undergone coronary imaging (e.g., coronary CT angiogram)?
I am a 57-year-old with late‑onset arthritis; is it appropriate to start immunoglobulin (IG) therapy?
In a patient with normal Glasgow Coma Scale, pH 7.34, bicarbonate 28 mmol/L, PaCO₂ 35 mm Hg and alcohol intoxication, should additional sodium bicarbonate be administered?
Should all four CRAB criteria (hypercalcemia, renal insufficiency, anemia, bone lesions) be required for the diagnosis of active multiple myeloma?
Why is calcium gluconate administered as a slow intravenous infusion rather than a rapid bolus in the treatment of hypocalcemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.